Oxford Biomedica and Sigma-Aldrich win key ruling in open biosystems patent infringement dispute
Oxford BioMedica and Sigma-Aldrich announced that they received a key order confirming the strength and validity of intellectual property owned by Oxford BioMedica and licensed exclusively in the research field to Sigma-Aldrich. The ruling was part of the construction of patent claim terms in the patent infringement suit brought against Open Biosystems, Inc.
The lawsuit, which is pending in the U.S. District Court for the Eastern District of Missouri, alleges that Open Biosystems infringes U.S. Patent Nos. 6,924,123 and 7,056,699 entitled Lentiviral LTR Deleted Vector, which are owned by Oxford BioMedica and exclusively licensed to Sigma-Aldrich for research use, by selling, among other products, Open Biosystems' Lentiviral shRNAmir Library. In his order U.S. District Judge Charles A. Shaw concluded "that the constructions of the disputed terms and phrases proposed by plaintiff are correct."
Organizations
Other news from the department politics & laws

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
TSRI and St. Jude scientists study single 'transformer' proteins with role in cancer

Novel PET tracer detects small blood clots
Researchers identify a new mode of drug resistance to emerging therapies in prostate cancer
Drug that modifies gene activity could help some older leukemia patients
Anemia drugs does not improve health of anemic heart failure patients
Merck and Biocartis to Collaborate

Better than Humans: Artificial Intelligence in Intensive Care Units - An AI can suggest appropriate treatment steps in cases of blood poisoning: The computer has already surpassed humans in this respect
Basilea opens new phase III study in special patient populations for its broad-spectrum antifungal isavuconazole
Elevated Testosterone Kills Nerve Cells
Cenix BioScience and ugichem sign research agreement on development of novel gene silencing technology.
